These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8900866)

  • 1. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. part 6: rifampicin.
    Ammar HO; Khalil RM
    Pharmazie; 1996 Mar; 51(3):165-8. PubMed ID: 8900866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrepancy among dissolution rates of commercial tables as a function of the dissolution method. Part 7: Aspirin.
    Ammar HA; el-Nahhas SA; Emara LH; Ghorab MM; Salama HA
    Pharmazie; 1997 Feb; 52(2):145-9. PubMed ID: 9122273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. Part 5: In vitro/in vivo correlation for chlorpromazine hydrochloride tablets.
    Ammar HO; Khalil RM; Omar SM
    Pharmazie; 1993 Dec; 48(12):932-5. PubMed ID: 8115438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroretentive delivery of rifampicin: in vitro mucoadhesion and in vivo gamma scintigraphy.
    Pund S; Joshi A; Vasu K; Nivsarkar M; Shishoo C
    Int J Pharm; 2011 Jun; 411(1-2):106-12. PubMed ID: 21458549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms.
    Agrawal S; Panchagnula R
    Pharmazie; 2004 Oct; 59(10):775-81. PubMed ID: 15544056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
    Ashokraj Y; Agrawal S; Varma MV; Singh I; Gunjan K; Kaur KJ; Bhade SR; Kaul CL; Caudron JM; Pinel J; Panchagnula R
    Int J Tuberc Lung Dis; 2004 Sep; 8(9):1081-8. PubMed ID: 15455592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bioavailability of diazepam from uncoated tablets in humans--Part I: correlation with the dissolution rates of the tablets.
    Ogata H; Aoyagi N; Kaniwa N; Koibuchi M; Shibazaki T; Ejima A; Tsuji S; Kawazu Y
    Int J Clin Pharmacol Ther Toxicol; 1982 Apr; 20(4):159-65. PubMed ID: 7076345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of ciprofloxacin tablets in humans and its correlation with the dissolution rates.
    Khan MK; Khan MF; Khan H; Mustafa G
    Pak J Pharm Sci; 2009 Jul; 22(3):329-34. PubMed ID: 19553184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance.
    Agrawal S; Ashokraj Y; Bharatam PV; Pillai O; Panchagnula R
    Eur J Pharm Sci; 2004 Jun; 22(2-3):127-44. PubMed ID: 15158898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro availability of commercial vitamin C tablets.
    Zia H; Amini H; Hekmatyar F; Needham TE
    Pahlavi Med J; 1977 Oct; 8(4):414-58. PubMed ID: 927874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative dissolution rate studies of commercial furosemide tablets.
    Gadalla MA; Ismail AA
    Pharmazie; 1981 Aug; 36(8):553-6. PubMed ID: 7291288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
    Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
    Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
    Agrawal S; Panchagnula R
    Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative bioavailability of three commercial acetaminophen tablets.
    Hekimoğlu S; Ayanoğlu-Dülger G; Hincal AA
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):93-6. PubMed ID: 3557735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lot-to-lot variation in dissolution of tolbutamide tablets.
    Ayres JW
    Am J Hosp Pharm; 1980 Oct; 37(10):1329-32. PubMed ID: 7424928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of nalidixic acid from uncoated tablets in humans--Part I: Correlation with the dissolution rates of the tablets.
    Ogata H; Aoyagi N; Kaniwa K; Shibazaki T; Ejima A; Takasugi N; Mafune E; Hayashi T; Suwa K
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):175-83. PubMed ID: 6715086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
    Agrawal S; Panchagnula R
    Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two dissolution apparatuses: rotating basket versus rotating flask.
    Koch HP; Alcorn G; Ritschel WA
    Pharmazie; 1983 Apr; 38(4):233-5. PubMed ID: 6867085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.